Luvometinib in Combination With Serplulimab for NF2-Related Tumors

Clinical trial NCT07708285 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07708285
Sponsor: Beijing Tiantan Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

NF2-related Schwannomatosis NF2 Neurofibromatosis Type 2 Vestibular Schwannoma Meningioma

Start date: 2026-07-31
Primary completion: 2028-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.